These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 17427642)

  • 21. Long-Term Outcomes and Predictors of Sustained Response in Patients with Intestinal Behcet's Disease Treated with Infliximab.
    Zou J; Ji DN; Cai JF; Guan JL; Bao ZJ
    Dig Dis Sci; 2017 Feb; 62(2):441-447. PubMed ID: 28044230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Case of neuro-Behçet's disease successfully maintained a remission using infliximab for 2 years.
    Kanemaru H; Makino T; Jinnin M; Yonemitsu A; Makino K; Ihn H
    J Dermatol; 2013 Aug; 40(8):632-4. PubMed ID: 23724912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behçet's syndrome refractory to the conventional treatment modalities: a case series and review of the literature.
    Hatemi I; Hatemi G; Pamuk ON; Erzin Y; Celik AF
    Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S129-37. PubMed ID: 26486925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of ocular Behçet's disease remission after short-term treatment with infliximab: a case series of 11 patients with a follow-up from 4 to 16 years.
    Sfikakis PP; Arida A; Ladas DS; Markomichelakis N
    Clin Exp Rheumatol; 2019; 37 Suppl 121(6):137-141. PubMed ID: 31856941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of infliximab in patients with intestinal Behçet's disease refractory to conventional medication.
    Kinoshita H; Kunisaki R; Yamamoto H; Matsuda R; Sasaki T; Kimura H; Tanaka K; Naganuma M; Maeda S
    Intern Med; 2013; 52(17):1855-62. PubMed ID: 23994973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An incomplete form of childhood Behçet's disease treated with infliximab.
    Caporuscio S; Pranteda G; Nistico S; Maucione T; Canzoni M; Stefani A; Muscianese M; Fanto M; Sorgi M
    Int J Immunopathol Pharmacol; 2014; 27(3):445-8. PubMed ID: 25280037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Behçet's disease - Infliximab in the treatment of mucocutaneous manifestations].
    Lestre S; Trindade F; Martins A; Baptista J; Feio AB; Lopes MJ
    Acta Reumatol Port; 2009; 34(4):633-40. PubMed ID: 20852576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Efficacy and safety of anti-tumor necrosis factor α monoclonal antibodies in 16 patients with severe/refractory vasculo Behcet's disease].
    Li L; Liu JJ; Yu X; Wu D; Zhang SZ; Yang YJ; Zhou JX; Zeng XF; Zhang FC; Zheng WJ
    Zhonghua Nei Ke Za Zhi; 2020 Apr; 59(4):303-308. PubMed ID: 32209197
    [No Abstract]   [Full Text] [Related]  

  • 29. Psoriasis triggered by infliximab in a patient with Behçet's disease.
    Kawazoe Y; Sugita S; Yamada Y; Akino A; Miura K; Mochizuki M
    Jpn J Ophthalmol; 2013 Jan; 57(1):95-7. PubMed ID: 23090423
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improvement of neurological and ocular symptoms of Behçet's disease after the introduction of infliximab.
    Barešić M; Reihl M; Habek M; Vukojević N; Anić B
    Rheumatol Int; 2018 Jul; 38(7):1301-1306. PubMed ID: 29777341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of anti-tumour necrosis factor alpha (infliximab) on sight-threatening uveitis in a patient with Behçet's disease.
    Morris DS; Gavin MP; Sturrock RD
    Adv Exp Med Biol; 2003; 528():557-9. PubMed ID: 12918763
    [No Abstract]   [Full Text] [Related]  

  • 32. Behçet's disease; A rare refractory patient with vena cava superior syndrome treated with infliximab: a case report and review of the literature.
    Uyaroglu OA; Erden A; Kilic L; Peynircioğlu B; Karadag O; Kalyoncu U
    Acta Clin Belg; 2019 Oct; 74(5):364-369. PubMed ID: 30220250
    [No Abstract]   [Full Text] [Related]  

  • 33. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
    Accorinti M; Pirraglia MP; Paroli MP; Priori R; Conti F; Pivetti-Pezzi P
    Jpn J Ophthalmol; 2007; 51(3):191-6. PubMed ID: 17554481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Late response to anti-TNF-α therapy in refractory mucocutaneous lesions of Behçet's disease.
    Aikawa NE; Gonçalves C; Silva CA; Gonçalves C; Bonfá E; de Carvalho JF
    Rheumatol Int; 2011 Aug; 31(8):1097-9. PubMed ID: 20012049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful treatment of severe Behçet's disease with infliximab in an Italian Olympic athlete.
    Olivieri I; Latanza L; Siringo S; Peruz G; Di Iorio V
    J Rheumatol; 2008 May; 35(5):930-2. PubMed ID: 18464316
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful use of infliximab in a patient with neuro-Behçet's disease.
    Abalos-Medina GM; Sánchez-Cano D; Ruiz-Villaverde G; Ruiz-Villaverde R; Quirosa Flores S; Raya Alvarez E
    Int J Rheum Dis; 2009 Sep; 12(3):264-6. PubMed ID: 20374357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet's disease: indication of anti-TNFα monoclonal antibodies.
    Hisamatsu T; Ueno F; Matsumoto T; Kobayashi K; Koganei K; Kunisaki R; Hirai F; Nagahori M; Matsushita M; Kobayashi K; Kishimoto M; Takeno M; Tanaka M; Inoue N; Hibi T
    J Gastroenterol; 2014 Jan; 49(1):156-62. PubMed ID: 23955155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful treatment of recalcitrant genital ulcers of Behçet's disease with adalimumab after failure of infliximab and etanercept.
    Olivieri I; D' Angelo S; Padula A; Leccese P; Mennillo GA
    Clin Exp Rheumatol; 2009; 27(2 Suppl 53):S112. PubMed ID: 19796550
    [No Abstract]   [Full Text] [Related]  

  • 39. Behçet's disease: a new target for anti-tumour necrosis factor treatment.
    Sfikakis PP
    Ann Rheum Dis; 2002 Nov; 61 Suppl 2(Suppl 2):ii51-3. PubMed ID: 12379622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-tumor necrosis factor alpha antibody in the treatment of Behçet's disease.
    Nakamura S; Ohno S
    Int Ophthalmol Clin; 2005; 45(2):179-89. PubMed ID: 15791165
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.